Chinese biopharmaceutical enterprise Gan & Lee Pharmaceuticals has signed a cooperation commitment letter for the PDP Project with Brazil's Ministry of Health, marking a new milestone in Sino-Brazilian biopharmaceutical collaboration.

The agreement, signed on Monday at Gan & Lee's headquarters in Beijing, as Alexandre Padilha, Brazil's Minister of Health, led a delegation accompanied by Heraldo Marchezini, CEO of Brazilian pharmaceutical company Biomm, on a visit to Gan & Lee. During the visit, they held strategic talks with Du Kai, CEO of Gan & Lee, and formally signed a cooperation agreement for the PDP project, a key initiative under Brazil's National Public Health System. 

It establishes Gan & Lee as the first Chinese pharmaceutical company to participate in Brazil's PDP program, marking a new phase of technological collaboration and industrial synergy between China and Brazil in the biopharmaceutical sector. The partnership will significantly advance Brazil's efforts in localizing insulin production while contributing to global diabetes prevention and treatment. 

Alexandre Padilha, Brazil's Minister of Health, emphasized the national strategic importance of this collaboration. He said the PDP project will not only guarantee medication accessibility for Brazilian diabetes patients but will also systematically upgrade Brazil's biopharmaceutical capabilities, establishing the foundation for domestic insulin production. 

"We consider this cooperation as a crucial starting point for deepening strategic relations between Brazil and Gan & Lee Pharmaceuticals, with expectations to expand into the broader healthcare area in the future," he said during the signing ceremony in Beijing on Monday. 

The PDP project is a critical component of Brazil's public health system reform, designed to strengthen healthcare infrastructure and ensure stable supplies of essential medicines. This agreement was formalized during Brazilian President Luiz Inacio Lula da Silva's state visit to China, following the approval of Gan & Lee Pharmaceuticals' insulin PDP project in February this year and subsequent April discussions with Brazil's Ministry of Health meetings conducted at Biomm's invitation. 

Heraldo Marchezini, CEO of Biomm, said that the collaboration marks the official launch of localized insulin glargine production in Brazil through the partnership between Brazil's state-funded medical research center Fiocruz, Gan & Lee Pharmaceuticals, and Biomm, which will significantly enhance diabetes treatment standards in the country. 

He emphasized that this initiative not only alleviates current insulin shortages, but also expands treatment access for Type 2 diabetes patients, representing a major advancement for Brazil's healthcare system. 

Over the past few years, Gan & Lee pharmaceuticals has continuously increased its efforts in innovative drug development and international market expansion. Particularly in emerging markets, Gan & Lee has established international partnerships and business activities with over 20 countries and regions along the Belt and Road Initiative.